CTIC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (24 Jun 2023 @ 03:58):

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States...

Stats
今日成交量	5.56M
平均成交量	5.66M
市值	1.20B
EPS	$0 ( 2024-03-04 )
下一个收益日期	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.84
ATR14	$0.183 (2.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-26	Bvf Partners L P/il	Sell	43 139	Common Stock, par value $0.001
2023-06-26	Bvf Partners L P/il	Sell	12	Series X Convertible Preferred Stock
2023-06-26	Bvf Partners L P/il	Sell	17	Series X1 Convertible Preferred Stock
2023-06-26	Bvf Partners L P/il	Sell	120 000	Stock Option (Right to Buy)
2023-06-26	Bvf Partners L P/il	Sell	60 000	Stock Option (Right to Buy)

INSIDER POWER
-81.65
Last 99 transactions
Buy: 2 253 317 \| Sell: 15 023 868

音量相关性

長: 0.20 (neutral)

短: -0.41 (neutral)

Signal:(83.616) Neutral

CTI Biopharma Corp 相关性

10 最正相关
APYX	0.961
DRNA	0.957
DMRC	0.956
EVLV	0.956
IZEA	0.952
BOXL	0.95
CELH	0.947
GT	0.944
GSMG	0.943
ALBO	0.942

10 最负相关
ITI	-0.951
MBIN	-0.937
VRCA	-0.928
CPRX	-0.928
AMPH	-0.922
INOD	-0.922
SPPI	-0.921
NVCT	-0.914
SLMBP	-0.914
PMTS	-0.913

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CTI Biopharma Corp 相关性 - 货币/商品

-0.06
( neutral )

0.32
( neutral )

0.00
( neutral )

0.06
( neutral )

0.69
( moderate )

0.32
( neutral )

CTI Biopharma Corp 财务报表

Annual	2022
营收:	$53.95M
毛利润:	$50.43M (93.49 %)
EPS:	$-0.790

FY	2022
营收:	$53.95M
毛利润:	$50.43M (93.49 %)
EPS:	$-0.790

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.090

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.740

Financial Reports:

No articles found.

CTI Biopharma Corp

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.